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1. Introduction 
Abnormal mineral metabolism and severe secondary hyperparathyroidism play a key role 
in the pathophysiology of skeletal and extraskeletal calcification and are associated with 
increased morbidity and mortality among hemodialysis (HD) patients (Block GA et al., 1998, 
2004; Ganesh et al., 2001; London GM et al., 2003). As a result of these findings, the National 
Kidney Foundation introduced guidelines in 2003 on controlling parathyroid hormone 
(PTH), calcium (Ca), phosphorous (P) and calcium-phosphorous ion product (CaxP) in these 
patients (National Kidney Foundation-Kidney Disease Outcomes and Quality Initiative, 
2003). However, in spite of the publication of the K/DOQI guidelines, most HD patients 
remained outside the recommended targets (Al Aly et al., 2004; Arenas et al., 2006; Lorenzo 
et al., 2006; Maduell et al., 2005). Historically, Ca-containing phosphate binders and vitamin 
D have provided the main strategies for reducing P and PTH levels (Slatopolsky et al., 1986). 
However, the overuse of Ca-containing phosphate binders and active vitamin D can result 
in hypercalcemia, high CaxP level and Ca overload, which may accelerate vascular disease 
and hasten death. These side effects potentially require temporary cessation of vitamin D 
and a reduction in Ca-containing binder administration. This cycle results in a temporary 
worsening of secondary hyperparathyroidism, allowing bone disease progression (Block et 
al., 1998, 2000; Johnson et al., 2002; Moe et al., 2003). Hence, new treatment strategies are 
required (Jindal et al., 2006; Moe et al., 2009;). 
Since 2006, two new drugs, paricalcitol and cinacalcet, have been available in daily clinical 
practice for secondary hyperparathyroidism treatment. Paricalcitol is a vitamin D metabolite 
that has some advantages over calcitriol, the standard form of vitamin D used worldwide. 
Paricalcitol suppresses PTH faster than calcitriol (Sprague et al., 2001), and may have a 
lesser Ca and P intestinal absorption capacity, with smaller increases in Ca and P serum 
(Llach et al., 2001). Patients who receive paricalcitol may also have a significant survival 
advantage over those who receive calcitriol (Teng et al., 2003). Despite these advantages, the 
occurrence of hypercalcemia and high CaxP, when high doses of paricalcitol are used, is not 
unusual (Goodman, 2001; Martin & Gonzalez, 2001). 
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Cinacalcet, the first calcimimetic available, has provided a new approach for severe 
secondary hyperparathyroidism. It increases the sensitivity of the Ca-sensing receptor on 
the parathyroid cell surface to extracellular Ca ions, thereby inhibiting the release of PTH. 
All clinical trials concluded that cinacalcet is effective in reducing PTH while 
simultaneously lowering Ca, P and CaxP levels in HD patients (Block et al, 2004; Goodman 
et al., 2002; Lindberg et al., 2005; Quarles et al., 2003). All these effects could facilitate 
achievement of the K/DOQI recommended targets (Block et al., 2008; Messa et al, 2008; Moe 
et al., 2005). 
Given the difficulty of achieving K/DOQI targets, and the absence of treatment algorithms 
that take into account both drug treatment (conventional drugs like phosphate binders, and 
new drugs like paricalcitol and cinacalcet) and HD features, such as the length of dialysis 
session or the dialysate Ca concentration recommended, our HD Unit has, since 2006, 
implemented a new treatment protocol for controlling bone metabolism parameters. The 
aim of our study was to evaluate the long-term effect of applying this protocol on achieving 
K/DOQI targets. 
2. Materials and methods  
2.1 Study design 
This is a single-centre, intervention study. HD patients were eligible for inclusion if they were 
adults (age ≥18 years) and if they had attended our HD unit for at least 3 months from Jan 2006 
to April 2008. Patients who had been on HD therapy for less than 3 months, or who presented 
excessively suppressed parathyroid hormone (PTH <10 pg/mL) secondary to previous 
parathyroidectomy, were excluded. Starting in April 2006, the new protocol treatment was 
applied to 52 of the 57 patients attending our unit over this two year period. Five patients were 
excluded (in every case because of a stay in our HD unit of less than 3 months).  
2.2 Interventions 
This intervention study consisted of three stages: an assessment stage 3 months before 
applying the protocol (base period), and the 12 and 24 month effectiveness assessment 
phases. During the base period (January-March 2006), calcitriol was the only drug available 
for hyperparathyroidism treatment, and a bath containing 2.5 mEq/L of Ca was 
preferentially used, as K/DOQI guidelines recommended. Since April 2006, treatment for 
control bone metabolism parameters, including cinacalcet administration, has been adjusted 
according to our new protocol. All patients treated with calcitriol, were changed to 
paricalcitol. Dialysate Ca content was determined individually, based on the protocol. In all 
three stages, Ca acetate was the only Ca-containing phosphate binder used, in order to limit 
the total dosage of elemental Ca provided. The preferred non-Ca phosphate binder used 
was sevelamer, up to a maximum dose of 4800 mg per day. Only if P remained >5.5 mg/dL, 
in spite of full doses of Ca acetate and sevelamer, was treatment with aluminium hydroxide 
considered. In line with K-DOQI guidelines, we tried to maintain serum Ca levels within the 
normal range for our laboratory (8.4-10.2 mg/dL), and preferably towards the lower end 
(8.4-9.5 mg/dL); P below 5.5 mg/dL; CaxP below 55 mg2/dL2; and PTH levels between 150 
and 300 pg/mL. The protocol consisted in three treatment algorithms, depending on the 
PTH level. When parathyroid hormone level was less than 150 pg/mL (Figure 1), depending 
on Ca levels, the dose of cinacalcet or paricalcitol was reduced gradually, until a minimum 
dose (oral cinacalcet, 30 mg three times per week; intravenous paricalcitol, 2.5 µg once per 
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week) was reached. If PTH levels continued to be oversuppressed, we considered a 
reduction in dialysate Ca concentration from 3.0 to 2.5 mEq/L or a reduction in the dose of 
Ca acetate, in order to stimulate the PTH secretion.  
 
 
Fig. 1. Algorithm treatment when parathyroid hormone level was less than 150 pg/mL.  
When parathyroid hormone level was within the target range (Figure 2), osteodystrophy 
treatment was modified according to Ca and P levels. If Ca levels ≥9.5 mg/dL and P levels 
were within the range, the doses of paricalcitol or Ca acetate were reduced. A reduction in 
dialysate calcium concentration to 2.5 mEq/L was also considered. If P levels were >5.5 
mg/dL and Ca levels were within the range, we increased the dose of phosphate binders 
and we considered lengthening the time of dialysis session. If both Ca and P levels were too 
high, Ca acetate was replaced by non-Ca phosphate binders and paricalcitol dosage was 
reduced or replaced by cinacalcet. In this case, we also considered a reduction in dialysate 
Ca concentration to 2.5 mEq/L and an increase in the length or frequency of dialysis session. 
 
 
Fig. 2. Algorithm treatment when parathyroid hormone level was within the target range.  
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When parathyroid hormone was over 300 pg/mL (Figure 3),  and Ca <9.5 mg/dL, dialysate 
Ca concentration were raised from 2.5 to 3.0 mEq/L, and we increased paricalcitol or 
cinacalcet, depending on whether the P and CaxP levels were normal or too high, 
respectively. Increases in the length of dialysis session and in the Ca acetate dosage were 
also considered. When Ca levels were between 9.5 to 10.2 mg/dL and CaxP <55 mg2/dL2, 
cinacalcet was preferentially used. If PTH remained too high, in spite of full doses of 
cinacalcet, we considered changing Ca acetate to sevelamer and increasing dialysate Ca 
concentration or adding low doses of paricalcitol, carefully monitoring CaxP levels. When 
Ca levels were too high or within the high-normal range and CaxP >55 mg2/dL2, paricalcitol 
was reduced or withdrawn and the cinacalcet dosage was increased. We also considered 
increasing the length or frequency of dialysis session and the dosage of non-Ca phosphate 
binders, and reducing the dialysate Ca concentration. 
 
 
Fig. 3. Algorithm treatment when parathyroid hormone was over 300 pg/mL. 
2.3 Laboratory tests  
All blood samples were collected at the start of the dialysis session following the longest 
interdialysis period. The samples were analyzed for serum Ca, P and intact PTH. All K-
DOQI parameters were measured at least monthly. In total, 863 blood samples were 
analyzed (median: 16.9 samples per patient). Total serum Ca and P were measured by 
colorimetric assay (Roche Diagnostics GmbH, Mannheim, Germany), the reference value for 
serum calcium being 8.6–10.4 mg/dL and for phosphate 3.5–5.5 mg/dL. The serum levels of 
total Ca were adjusted for circulating albumin levels (reference values: 3.4-4.8 g/dL). 
Albumin levels were assessed by Albumin BCG Method (Roche Diagnostics GmbH, 
Mannheim, Germany). PTH levels were assessed by an electrochemiluminescence 
immunoassay (Elecsys, Roche Diagnostics GmbH, Mannheim, Germany). The reference 
range for healthy adults is 15–65 pg/mL.  
2.4 Renal replacement therapy 
Patients received standard HD or post-dilution hemodiafiltration (HDF) treatment, lasting 
between 3h and 4h30m, three times per week.Dialysis prescription was monitored to 
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maintain Kt/V>1.2- Polysulphone or AN69st membrane dialysers were used. Blood flow 
was at least 300mL/min and dialysate flow 750 mL/min. Dialysate composition was Ca 2.5 
or 3.0, Na 139 or 140, K 1.5 or 1.9, bicarbonate 34, 37 or 40.8, mEq/L. Infusate composition 
for patients on HDF was Na 145, Cl 85, bicarbonate 60 mmol/L, with an infusion flow of 2 
L/hour. The dialysis equipment employed was Bellco® or Hospal®.  
2.5 Statistics 
Student’s unpaired t-test was used to compare the three phase means of all PTH, Ca, P and 
CaxP values. The proportion of patients within K/DOQI target ranges over the 2 years 
following the implemention of the protocol was used to evaluate effectiveness. Percentages 
were compared using the chi-square test. We analyzed potential factors involved in the 
evolution of bone metabolism parameters, such as phosphate binder dosage, the cinacalcet 
and paricalcitol used, and the features of HD employed. Results are expressed as mean and 
standard deviation. A multivariate analysis of the factors associated with the achievement of 
all four K/DOQI target ranges during the last year were assessed using logistic regression 
analysis. A value of p<0.05 was considered statistically significant. 
3. Results 
3.1 Patients 
Fifty-two patients were studied, twenty-nine men and twenty-three women, 66.7±17.7 years 
old (range, 25 to 86 years) with a mean time on HD therapy of 71±84 months (range, 4 to 318 
months). The etiology of renal failure was hypertensive nephrosclerosis (n=12), diabetic 
nephropathy (n=10), glomerulonephritis (n=9), interstitial nephritis (n=8), polycystic kidney 
disease (n=2), Alport’s syndrome (n=1), and undetermined (n=10). The demographics of the 
patients studied at each stage of the study are summarized in Table 1. Mean observation 
time was 16.7±9.4 months. 
 
 Baseline 1 year 2 years 
Number of patients dialysed 30 36 43 
Number of prevalent patients 25 28 30 
Number of incident patients 5 8 13 
Mean age of patients (years) 
67.7 ± 16.9 
(25 - 84) 
67.2 ± 17.3 
(25 - 85) 
66.6 ± 16.4 
(31 - 86) 
Mean time on HD (months) 
113 ± 89 
(12 - 294) 
94 ± 89 
(6 - 306) 
70 ± 86 
(3 - 318) 
Mean serum albumin (g/dL) 
3.8 ± 0.3 
(3.5 - 4.6) 
3.8 ± 0.3 
(2.8 - 4.6) 
3.7 ± 0.4 
(2.5 - 4.6) 
% of diabetic patients 20%(6) 17%(6) 26%(11) 
Table 1. Demographic characteristics of patient population at each stage of the study.  
3.2 Evolution of biochemical parameters 
Changes in the adjusted Ca (CaAlb), P, CaxP, and PTH levels before and after implementing 
the protocol are shown in Table 2. CaAlb, CaxP and PTH levels decreased significantly 
throughout the study, with a mean decrease of 3.5% (p=0.016), 8.2% (p=0.023) and 39.4% 
(p=0.002), respectively. Although there was a reduction in P levels, the difference did not 
reach statistical significance (p=0.075).  
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 Baseline 1 year 2 years p 
CaAlb (mg/dL) 
9.46 ± 0.57 
(8.26 - 10.45) 
9.20 ± 0.529 
(7.54 – 10.24) 
9.13 ± 0.56 
(7.35 – 10.40) 
0.016 
P (mg/dL) 
4.97 ± 1.09 
(3.29 - 7.91) 
4.62 ± 0.94 
(3.02 - 6.7) 
4.56 ± 0.84 
(3.05 - 6.79) 
0.075 
CaxP (mg2/dL2) 
47.36 ± 11.33 
(29.97 - 79.81) 
42.58 ± 9.03 
(27.10 - 63.26) 
41.65 ± 8.27 
(26.91 - 65.52) 
0.023 
PTH (pg/mL) 
343 ± 209 
(11 - 864) 
239 ± 126 
(36 - 678) 
208 ± 107 
(42 - 704) 
0.002 
Table 2. Evolution of Biochemical Parameters. 
Mean corrected calcium, serum phosphorus, ion calcium-phosphorus product, and intact 
parathyroid hormone levels at each stage of the study were compared using Student’s 
unpaired t-test.  
3.3 Achievement of K/DOQI target levels  
The percentages of patients achieving the K/DOQI targets are summarized in Figure 4. In 
the base period, the proportion of patients achieving P, CaxP and PTH targets were 67%, 
73% and 13% respectively. An improvement in the achievement of these three targets was 
observed, reaching 84%, 93% and 72% of patients, respectively. This improvement was 
significant in CaxP and PTH levels (p=0.024 and p<0.001, respectively). The increase in the 
percentage of patients achieving P target did not reach statistical significance (p=0.074). The 
proportion of patients achieving CaAlb levels remained above 90% throughout the study 
(p=0.644). Overall, the rate of patients with all four K-DOQI parameters within target ranges 
improved significantly from 10.0 at baseline, to 33.3% (p=0.023) and to 60.5% (p<0.001) 
during the first and second year after implementing the protocol, respectively (Figure 5). 
 
 
Fig. 4. Percentage (%) of patients achieving each K/DOQI target by time period. 
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Fig. 5. Percentage (%) of patients achieving all four K/DOQI targets by time period.  
3.4 Medication use 
Treatment of osteodystrophy over time is shown in Table 3. As the protocol stated, all 
patients treated with calcitriol were changed to paricalcitol, which was administered to 
approximately a third of the patients throughout the study. Cinacalcet was the other drug 
available for HPT, and was administered to 22% and 26% of patients during the first and 
second year after implementing the protocol, respectively. Two drugs were administered in 
combination to 5 (12%) and 6 (14%) patients in each assessment stage. Ca acetate was the 
only calcium-based phosphate binder used, and the proportion of patients receiving this 
drug remained unchanged (70% of patients, approximately). The mean total dosage of 
elemental calcium provided by calcium acetate increased from 451±151 to 562±275 mg/day 
without statistical significance (p=0.079). The proportion of patients under treatment with 
aluminium hydroxide at the start of the study was significantly reduced from 20% (n=6) to 
5% (n=2) (p=0.047). Its dose remained unchanged throughout the study. 
Mean total dosage of calcium acetate is expressed as elemental calcium provided by calcium 
acetate. Mean doses were compared using Student’s unpaired t-test. Percentages were 
compared using the chi-square test. Abbreviations: n: number of patients; n.a.: not 
applicable. †Mean dose of aluminium hydroxide cannot be computed because the standard 
deviations of both groups were 0.  
3.5 Renal replacement therapy 
Changes in HD features over time are shown in Table 4. After implementing the protocol, a 
3.0 mEq/L dialysate Ca concentration became the most widely used (7% vs. 72%; p=0.001), 
and a significant increase in the proportion of patients under convective therapy was 
detected (30% vs. 67%; p=0.034). The length of dialysis session and the HD dose remained 
unchanged.  
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Baseline 
(n=30) 
1 year 
(n=36) 
2 years 
(n=43) 
p 
Rocaltrol 
n, (%) patients on treatment 
mean dose (µg/week) 
13 (43%) 
1.44 ± 0.21 
(0.75 - 1.50) 
- - 
n.a. 
n.a. 
Paricalcitol 
n, (%) patients on treatment 
mean dose (µg/week) 
- 
16 (44%) 
9.93 ± 5.19 
(2.50 - 22.50) 
14 (33%) 
9.38 ± 4.87 
(5.00 – 20.00) 
n.a. 
n.a. 
Cinacalcet 
n, (%) patients on treatment 
mean dose (mg/day) 
- 
8 (22%) 
35.7 ± 17.8 
(15 - 60) 
11 (26%) 
45.0 ± 34.6 
(15 - 120) 
n.a. 
n.a. 
Calcium acetate 
n, (%) patients on treatment 
mean dose (mg/day) 
20 (67%) 
451 ± 151 
(254 - 762) 
28 (78%) 
553 ± 242 
(127 - 1143) 
28 (65%) 
562 ± 275 
(127 - 1143) 
0.547 
0.079 
Sevelamer 
n, (%) patients on treatment 
mean dose (mg/day) 
20 (67%) 
4760 ± 1916 
(2400 - 7200) 
22 (61%) 
4255 ± 1645 
(2400 - 7200) 
26 (61%) 
4062 ± 1662 
(800 - 7200) 
0.386 
0.179 
Aluminium hydroxide 
n, (%) patients on treatment 
mean dose (mg/day) 
6 (20%) 
699 ± 0 
(699 - 699) 
2 (6%) 
699 ± 0 
(699 - 699) 
2 (5%) 
699 ± 0 
(699 - 699) 
0.047 
† 
Table 3. Treatment of osteodystrophy at each stage of the study. 
 
 Baseline (n=30) 
1 year 
(n=36) 
2 years 
(n=43) 
p 
Dialysate Ca concentration, n (%) 
Patients with Ca 2.5 
Patients with Ca 3.0 
 
28 (93%) 
2 (7%) 
 
6 (17%) 
30 (83%) 
 
12 (28%) 
31 (72%) 
0.001 
Dialysis type, n (%) 
Hemodialysis 
Hemodiafiltration 
 
21 (70%) 
9 (30%) 
 
11 (31%) 
26 (69%) 
 
14 (33%) 
29 (67%) 
0.034 
Length of dialysis session 
(hours/week) 
11.2 ± 1.3 
(9.0 – 13.5) 
11.4 ± 1.3 
(9.0 – 13.5) 
11.6 ± 1.3 
(9.0 – 13.5) 
0.481 
Kt/V 
1.39 ± 0.24 
(0.90 – 1.84) 
1.50 ± 0.20 
(1.10-1.91) 
1.42 ± 0.22 
(1.01-1.90) 
0.439 
Table 4. HD features at each stage of the study. 
Student’s unpaired t-test was used to compare means of length of dialysis session and Kt/V 
values. Percentages were compared using the chi-square test. Abbreviations: n: number of 
patients; URR: urea reduction ratio.  
3.6 Factors associated with achieving K/DOQI targets 
Data on each group of patients within and outside all four K/DOQI target ranges during the 
last year were compared (Table 5). The use of cinacalcet (39% vs. 6%; p=0.017) and the use of 
a 3.0 mEq/L dialysate Ca concentration (85% vs. 53%; p=0.028) were significantly more 
frequent in the group of patients who achieved all K/DOQI targets than in the group 
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≤ 3 K/DOQI targets 
achieved (n=17) 
All 4 K/DOQI targets 
achieved (n=26) 
p 
Gender, n (%) 
Female 
Male 
 
9 (53%) 
8 (47%) 
 
10 (39%) 
16 (61%) 
 
0.267 
Age (years) 67.98 ± 15.88 65.62 ± 17.03 0.650 
Mean time on HD (months) 50.21 ± 55.56 82.17 ± 100.22 0.756 
Diabetes mellitus, n (%) 6 (35%) 5 (19%) 0.493 
Mean serum albumin (g/dL) 3.69 ± 0.41 3.76 ± 0.36 0.575 
Mean 25 OH vit D (ng/mL) 11.9 ± 4.5 12.4 ± 4.5 0.770 
Dialysate Ca concentration, n 
(%) 
Patients with Ca 2.5 
Patients with Ca 3.0 
 
8 (47%) 
9 (53%) 
 
4 (15%) 
22 (85%) 
 
0.028 
Dialysis type, n (%) 
Hemodialysis 
Hemodiafiltration 
 
7 (41%) 
10 (59%) 
 
7 (27%) 
19 (73%) 
 
0.259 
Length of dialysis session 
(hours/week) 
11.4 ± 1.4 11.5 ± 1.2 0.434 
Kt/V 1.37 ± 0.22 1.46 ± 0.21 0.178 
Residual diuresis†, n (%) 3 (18%) 7 (27%) 0.375 
Paricalcitol 
n, (%) patients on treatment 
mean dose (µg/week) 
 
4 (24%) 
8.13 ± 4.73 
 
10 (39%) 
9.79 ± 5.05 
 
0.247 
0.573 
Cinacalcet 
n, (%) patients on treatment 
mean dose (mg/day) 
 
1 (6%) 
30 
 
10 (39%) 
46.7 ± 36.6 
 
0.017 
0.909 
Calcium acetate 
n, (%) patients on treatment 
mean dose (mg/day) 
 
11 (65%) 
577 ± 323 
 
17 (65%) 
553 ± 250 
 
0.608 
0.434 
Sevelamer 
n, (%) patients on treatment 
mean dose (mg/day) 
 
10 (39%) 
4000 ± 1131 
 
16 (62%) 
4100 ± 1957 
 
0.554 
0.870 
Aluminium hydroxide 
n, (%) patients on treatment 
 
2 (12%) 
 
0 (0%) 
 
0.151 
 
Table 5. Characteristics of the patients who achieved all K/DOQI target ranges during the 
second year period and those who did not. Mean total dosage of calcium acetate is 
expressed as elemental calcium provided by calcium acetate. Student’s unpaired t-test was 
used to compare means. Percentages were compared using the chi-square test. 
Abbreviation: n, number of patients; 25 OH vit D, 25-Hydroxyvitamin D; URR, urea 
reduction ratio. † Residual diuresis is defined as diuresis >1000 mL/24h and residual KtV 
≥0.4. 
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outside ranges. Although there was a higher proportion of patients under paricalcitol 
treatment (39% vs. 24%) and convective therapy (73% vs. 59%) in the group achieving all 
targets, the differences did not reach statistical significance (p=0.247 and p=0.259, 
respectively). There were no differences in the use of phosphate binders or the dialysis dose. 
A multivariate analysis found that the use of a 3.0 mEq/L dialysate Ca concentration (OR 
5.756; 1.102-30.077; p=0.038) and treatment with cinacalcet (OR 12.684; 1.115-144.352; 
p=0.041) were the factors associated with achieving all K/DOQI targets. 
4. Discussion 
In spite of applying the K/DOQI Clinical Practice Guidelines for Bone Metabolism and 
Disease, achievement of K/DOQI targets reminds difficult. In 2006, coinciding with the 
availability in daily clinical practice of paricalcitol and cinacalcet, our HD Unit 
implemented a new treatment protocol for controlling the bone metabolism parameters 
better. As Figures 1, 2 and 3 show, this protocol consisted of three practical treatment 
algorithms, based on the use of cinacalcet and paricalcitol and the individualization of the 
dialysate Ca concentration employed, as the main strategies for hyperparathyroidism 
control, and of dialysis adequacy and combined therapy with sevelamer and Ca acetate 
for controlling Ca and P levels. Although other algorithms for controlling bone 
metabolism parameters have been developed (Cannata & Drueke, 2000; Messa et al, 2008; 
Torregrosa et al., 2011), this, we believe, is the first one to take into account both the drug 
treatment and HD features, such as the length of dialysis session or the dialysate Ca 
concentration recommended. 
Application of this new treatment protocol was effective and resulted in significant 
reductions in mean CaAlb, CaxP and PTH levels (Table 2), with a higher proportion of 
patients achieving the recommended goals. Noteworthy is the 60.5% of patients with all four 
K-DOQI parameters within target ranges in the second year after implementing the protocol 
(Figure 5). This improvement in K/DOQI targets maintained over time could have a direct 
impact in the survival of patients, given that the simultaneous control of all bone and 
mineral metabolisms have been showed to be associated with improved survival (Danese et 
al., 2008). 
Implementation of the protocol entailed the administration of paricalcitol and cinacalcet, a 
preferential use of convective therapies, and the most widely used dialysate Ca 
concentration of  3.0 mEq/L (Tables 4 and 5). However, it is not easy to assess which of the 
measures carried out, following  implementation of the protocol, has the greatest effect on 
improving the K/DOQI targets observed, given the multiple factors involved in PTH 
secretion and in Ca and P levels. We, therefore, compared the characteristics of the patients 
who achieved all K/DOQI target ranges during the second year of study and those who did 
not (Table 5). Although there was higher HD dose and a higher proportion of patients under 
paricalcitol treatment and convective therapy in the group within all the targets, a 
multivariate analysis showed that the use of a 3.0 mEq/L dialysate Ca concentration and the 
treatment with cinacalcet were the only two factors significantly associated with 
achievement of all K/DOQI targets.  
These findings are consistent with the literature. Cinacalcet, the first calcimimetic 
available in daily clinical practice, has proven effective for lowering PTH, Ca, P and CaxP 
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levels in HD patients (Block et al, 2004; Goodman et al., 2002; Lindberg et al., 2005;  
Quarles et al., 2003). This ability to lower PTH, while limiting the risks of 
hyperphosphatemia or hypercalcemia, has improved the achievement of the proposed 
treatment goals (Block et al., 2008; Messa et al., 2008; Moe et al., 2005), allowing it to be 
used synergistically in combination with vitamin D sterols (Chertow et al., 2006; Messa et 
al., 2008). Our protocol took this favourable and complementary effect of combined 
treatment into account: 60% of the patients who were on paricalcitol treatment and 
achieved all K/DOQI goals during the second year of study, also received treatment with 
cinacalcet. In conclusion, we cannot explain the great improvement in K/DOQI goals 
achieved throughout the study without the use of cinacalcet, either alone or in association 
with paricalcitol. It’s to note the absence of significant association between the use of 
paricalcitol and achievement of control of all K/DOQI targets. We think it might be 
related to the fact that 43% of the patients were previously treated with calcitriol. Hence 
it’s difficult to detect any advantages in improving bone metabolism parameters with the 
use of paricalcitol. Despite these results, we still recommend the preferential use of 
paricalcitol over calcitriol, given the benefits observed in other studies with the selective 
vitamin D receptor activation (Llach et al., 2001; Sprague et al.,2001; Teng et al.,  
2003).  
Greater use of a 3.0 mEq/L dialysate Ca concentration was the other factor significantly 
associated with achieving all K/DOQI targets (85% of patients within all targets). Although 
optimal dialysate Ca concentration for HD patients has been set at 2.5 mEq/L according to 
K-DOQI guidelines, this recommendation is opinion-based and could negatively affect 
secondary hyperparathyroidism (Argilés et al., 1998; Fernández, et al., 1995). Several studies 
have reported better control of secondary hyperparathyroidism, without risk of severe 
hypercalcemia, after raising the dialysate Ca concentration from 2.5 to 3.0 mEq/L (Argilés, 
1995; Malberti & Raviani, 2004; Molina et al., 2008). A Ca concentration of 3.0 mEq/L has, 
therefore, been suggested as the first choice for the majority of patients on HD (Cannata & 
Drueke, 2000; Torregrosa et al, 2011; Touissant et al., 2006). In any case, the best approach 
would be to individualize the prescription of dialysate Ca concentration, as the K-DOQI 
guidelines noted.  
Noteworthy is the absence of significant changes observed in the use of phosphate 
binders, with the exception of aluminium hydroxide, the use of which was significantly 
reduced, as evidence of better control of bone metabolism parameters. Although the 
proportion of patients receiving Ca acetate remained unchanged, the mean total dosage of 
elemental Ca provided showed a tendency to increase (451±151 vs 562±275 mg/day; 
p=0.079). The lack of statistical significance could be due to the limited number of 
patients. This raise in Ca provided by Ca-containing phosphate binders has been 
previously reported in another study with cinacalcet therapy (Block et al., 2008), where 
excessively high doses of Ca provided by binders were necessary in order to avoid 
hypocalcemia. In our study, however, the mean total dosage of elemental Ca provided 
remained below the maximum dose recommended by K/DOQI guidelines. We speculate 
that the relatively small average dose of cinacalcet used (45.0±34.6 mg/day), the 
preferential use of a dialysate Ca concentration of 3.0 mEq/L and the administration of 
paricalcitol could explain the absence of the need for excessively high doses of Ca acetate. 
Finally, we should emphasize the desirability of only using Ca acetate, as the Ca-
www.intechopen.com
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containing phosphate binder, in order to limit the total dosage of elemental Ca  
provided. 
The current study has several limitations. This was an intervention study without a control 
group. It would have been interesting to study additional markers of bone metabolism such 
as bone mass, skeletal fracture rates, cardiovascular calcification or arterial function, given 
that they could provide more valuable information on the overall assessment of renal bone 
disease than K-DOQI core measurement standard biomarkers. Other limitations of our 
study were the limited number of patients, which is common in a single-centre study. 
However, this was compensated for by the long follow-up period and the relatively high 
number of blood samples analyzed. 
5. Conclusion 
Two years after its implementation, the proposed treatment protocol for control bone 
metabolism parameters has greatly increased the achievement of K/DOQI treatment targets 
in most of the HD patients. The protocol entailed the administration of cinacalcet, the 
replacement of calcitriol by paricalcitol, and the incorporation of individual dialysate Ca 
concentration prescriptions into the algorithm, with a preferential use of a dialysate Ca 
concentration of 3.0 mEq/L.  
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